10-Q: Exicure Q1 2026 Financial Results and Going Concern Warning

Exicure reports a net loss of $1.8 million for Q1 2026 and warns of substantial doubt regarding its ability to continue as a going concern.

Summary

• Reported a net loss of $1.8 million for the three months ended March 31, 2026, compared to a net income of $3.0 million in the same period of 2025.
• Cash and cash equivalents decreased to $2.6 million as of March 31, 2026, from $3.7 million at year-end 2025.
• Operating expenses were $1.6 million for the quarter, driven by research and development and general administrative costs.
• Management explicitly states there is substantial doubt about the company's ability to continue as a going concern due to insufficient liquidity.
• The company is actively exploring strategic alternatives, including potential partnerships or business combinations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly distressed situation characterized by a going concern warning, material weaknesses in internal controls, and active litigation, leaving little room for operational recovery without a major capital injection or strategic pivot.

Positives

• Significant reduction in operating expenses, with R&D expenses down 61% and G&A expenses down 42% year-over-year.
• Successful completion of a Phase 2 clinical trial by subsidiary GPCR USA in January 2026.
• Formal settlement agreement reached in March 2026 regarding outstanding stockholder derivative lawsuits.

Negatives

• Net loss of $1.8 million for the quarter.
• Cash position of only $2.6 million, which is insufficient to fund operations for the next 12 months.
• Material weaknesses identified in internal control over financial reporting regarding non-routine accounting and IT processes.
• Received a Nasdaq deficiency notice due to the delayed filing of the Q1 2026 10-Q report.
• Legal dispute with Dren Bio regarding unpaid rent and potential eviction from Redwood City facilities.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern.
• Risk of delisting from the Nasdaq Capital Market due to non-compliance with listing rules.
• Potential for bankruptcy or cessation of operations if additional capital cannot be raised.
• Ongoing legal proceedings, including a breach of contract claim from a former employee with potential for significant damages.
• High dependency on the ability to raise capital through equity offerings, which would likely result in significant shareholder dilution.

Future Outlook

The company expects to incur significant expenses and negative cash flows for the foreseeable future. It is prioritizing the exploration of strategic alternatives and seeking additional capital, though there is no assurance that such efforts will be successful or on favorable terms.

Management Comments

• Management believes existing cash is insufficient to fund operations for the next 12 months.
• The company is working diligently to complete and file reports to regain Nasdaq compliance.
• Management is evaluating the material weaknesses in internal controls and developing a remediation plan.

Industry Context

StockSavvy.ai notes that Exicure's situation is characteristic of distressed micro-cap biotechnology firms that have exhausted their primary pipeline and are now pivoting to 'shell' status or seeking reverse merger candidates to preserve the value of their public listing.

Comparison to Industry Standards

• The company's reliance on equity financing to survive is common among pre-revenue biotech firms, but its current liquidity crisis is more severe than typical industry peers.
• The use of contingent consideration and milestone payments in the GPCR acquisition is standard in biotech M&A, though the inability to meet the first milestone payment highlights extreme financial distress.

Corporate Governance

Legal Proceedings

• Dren Bio vs. GPCR USA: Unlawful detainer complaint regarding unpaid rent of approximately $0.7 million.
• Securities Class Action: Settlement reached and approved in January 2025.
• Stockholder Derivative Lawsuits: Agreement in principle reached; formal settlement executed March 2026.
• Former Employee Breach of Contract: Ongoing litigation regarding separation and IWPCA claims; potential liability of $250,000 to $300,000 or higher.

Related Party Transactions

• Consulting agreement with Alta Companies LTD, owned by former director and CEO Paul Kang, involving monthly payments of $12,500.

Stakeholder Impact

• Shareholders face significant risk of dilution or total loss of value if the company cannot raise capital or execute a strategic alternative.
• Creditors and landlords are currently in dispute with the company over unpaid obligations.
• Employees face uncertainty due to the company's restructuring and potential for cessation of operations.

Next Steps

• Regain compliance with Nasdaq listing requirements by filing the 10-Q.
• Continue exploration of strategic alternatives, including potential business combinations.
• Address the legal dispute with Dren Bio regarding the Redwood City lease.
• Prepare for the June 2026 court hearings regarding legal settlements.

Key Dates

Recommendation

The combination of a going concern warning, material weaknesses in internal controls, and a severe liquidity crisis makes this stock extremely high-risk with a high probability of further dilution or total loss for common shareholders.

Keywords

Exicure, XCUR, Biotechnology, Going Concern, Strategic Alternatives, GPCR Therapeutics, Nasdaq Delisting, Clinical Trials